Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

withdrawn133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnnot_applicable

Lipiflow Versus Warm Compresses in Parkinson's Disease

NCT02894658
completednot_applicable

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

NCT01521507
completedphase_2

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

NCT01202747

Clinical Trials (3)

Showing 3 of 3 trials
NCT02894658Not Applicable

Lipiflow Versus Warm Compresses in Parkinson's Disease

Withdrawn
NCT01521507Not Applicable

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

Completed
NCT01202747Phase 2

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3